RDY Share Price

Open 36.48 Change Price %
High 37.40 1 Day 0.22 0.61
Low 35.93 1 Week 0.00 0.00
Close 36.37 1 Month 0.33 0.92
Volume 782068 1 Year -12.15 -25.04
52 Week High 49.41
52 Week Low 29.83
RDY Important Levels
Resistance 2 37.73
Resistance 1 37.17
Pivot 36.57
Support 1 35.57
Support 2 35.01
NYSE USA Most Active Stocks
RAI 65.40 -2.23%
RAI 65.40 -2.23%
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
GE 20.16 -1.22%
GE 20.16 -1.22%
GE 20.16 -1.22%
GE 20.16 -1.22%
GE 20.16 -1.22%
More..
NYSE USA Top Gainers Stocks
POM 26.93 26.79%
POM 26.93 26.79%
GLF 0.34 25.93%
GLF 0.34 25.93%
TREX 109.45 25.65%
HZO 18.55 22.04%
SSD 55.74 14.62%
TBI 27.10 14.11%
SSTK 38.99 13.84%
KAI 113.60 13.09%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Dr. Reddy's Laboratories Ltd (NYSE: RDY)

RDY Technical Analysis 2
As on 31st Oct 2017 RDY Share Price closed @ 36.37 and we RECOMMEND Sell for LONG-TERM with Stoploss of 40.14 & Strong Buy for SHORT-TERM with Stoploss of 34.61 we also expect STOCK to react on Following IMPORTANT LEVELS.
RDY Target for November
1st Target up-side 37.51
2nd Target up-side 38.32
3rd Target up-side 39.12
1st Target down-side 35.23
2nd Target down-side 34.42
3rd Target down-side 33.62
RDY Other Details
Segment EQ
Market Capital 5574793728.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.drreddys.com
RDY Address
RDY
Door No. 8-2-337
Road No 3
Hyderabad, 500034
India
Phone: 91 40 4900 2900
Fax: 91 40 4900 2999
RDY Latest News
Interactive Technical Analysis Chart Dr. Reddy's Laboratories Ltd ( RDY NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Dr. Reddy's Laboratories Ltd
RDY Business Profile
Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in the operation of biologics business. The Proprietary Products segment engages in the discovery and development of new chemical entities for subsequent commercialization and out-licensing. It offers new, synergistic combination, and technology formulations that modifies pharmacokinetics of existing medicines. This segment is also involved in the Company’s specialty pharmaceuticals business that includes sales and marketing operations for in-licensed and co-developed dermatology. The company offers its products and services primarily in the areas of gastrointestinal, cardiovascular, pain management, and oncology therapies. It primarily operates in India, the United States, Russia and other countries of the former Soviet Union, Europe, and others. The company has strategic partnership with Galena Biopharma for the development and commercialization of NeuVax, a immunodominant nonapeptide derived from the extracellular domain of the HER2 protein. Dr. Reddy’s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.